EP Patent

EP1831149B1 — Novel ligands that modulate rar receptors and use thereof in human medicine and in cosmetics

Assigned to Galderma Research and Development SNC · Expires 2012-01-25 · 14y expired

What this patent protects

The present invention relates to novel compounds corresponding to the general formula (I) below: to compositions containing them, to processes for preparing them and to their use in pharmaceutical compositions intended for use in human or veterinary medicine, or alternatively in …

USPTO Abstract

The present invention relates to novel compounds corresponding to the general formula (I) below: to compositions containing them, to processes for preparing them and to their use in pharmaceutical compositions intended for use in human or veterinary medicine, or alternatively in cosmetic compositions.

Drugs covered by this patent

Patent Metadata

Patent number
EP1831149B1
Jurisdiction
EP
Classification
—
Expires
2012-01-25
Drug substance claim
No
Drug product claim
No
Assignee
Galderma Research and Development SNC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.